* Neoadjuvant chemo is given before surgery to slow the growth of a fast growing cancer or to shrink the size of a larger breast cancer.
* So, neoadjuvant chemo is frequently used to treat locally advanced cancers, cancers that at the time of diagnosis are too big to be removed by surgery, which can then be removed with less extensive surgery.
* Adjuvant chemo is given after surgery to reduce the risk of recurrence. So, it is used to try to kill any cancer cells that might still exist and cannot be detected through imaging tests.
* Palliative chemo is used to control the cancer in settings in which the cancer has spread beyond the breast and localized lymph nodes. See metastatic breast cancer.
Combined therapies
* Combining, for example, non-drug treatments with localized chemotherapy to limit toxicity and achieve better results.
Regimens
Multiple chemotherapeutic agents may be used in combination to treat patients with breast cancer. Determining the appropriate regimen to use depends on many factors; such as, the character of the tumor, lymph node status, and the age and health of the patient. The following is a list of some of the commonly used adjuvant chemotherapy for breast cancer:
FEC: 5-fluorouracil, epirubicin and cyclophosphamide.
AT: Adriamycin and Taxotere.
Since chemotherapy affects the production of white blood cells, a granulocyte colony-stimulating factor is sometimes administered along with chemotherapy. This has been shown to reduce, though not completely prevent, the rate of infection and low white cell count. Most adjuvant breast cancer chemotherapy regimens do not routinely require growth factor support except for those associated with a high incidence of bone marrow suppression and infection. These may include chemotherapy given in the dose dense fashion i.e. 2-weekly instead of 3-weekly or TAC chemotherapy. In women with operable early breast cancer, taxane-containing adjuvant chemotherapy regimens have been found to improve overall survival and disease-free survival.
Anthracylines
By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines. CEP17 is detected by a common and straightforward test, which is carried out routinely in breast cancer patients; it is used to test for the HER2 gene to see whether the women might benefit from the drug Herceptin. Professor Bartlett said that assessment for CEP17 could be easily carried out in the same FISH analysis as for HER2. ]
Administration
For breast cancer, chemotherapy drugs are given into a vein or by mouth as tablets or capsules.
